glycogen phosphorylase inhibitor

AVE5688, an inhibitor of glycogen phosphorylase (GP), has IC50 values of 430 nM and 915 nM, and Kd values of 170 nM and 530 nM for rmGPb and rmGPa, respectively. It is suitable for research on type 2 diabetes.

Glycogen phosphorylase-IN-1 is a selective and potent inhibitor of human hepatic glycogen phosphorylase (hlGPa) with inhibitory effects on hlGPa activity and on hepatocyte glycogen-derived glucose production, and can be used in the study of type 2 diabetes mellitus and canine lupus.

Uric Acid (Lithic acid) is an oxidation product of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.

N6-Methyladenosine 5'-monophosphate disodium salt is a glycogen phosphorylase b activator and an inhibitor of adenylate kinase II.

BAY R3401 is an orally active inhibitor of glycogen phosphorylase, leading to irreversible and non-selective inhibition of liver glycogenolysis. It suppresses glycogen breakdown in hepatocytes with IC50 values of 27.06 μM in HL-7702 cells and 52.83 μM in HepG2 cells. BAY R3401 is applicable for research in type 2 diabetes.

CP-316819 (GPi 819) is a potent inhibitor of glycogen phosphorylase (GPase) with hypoglycemic effects, inhibits huSMGPa and huLGPa, maintains neuronal activity during hypoglycemia, and can be used in the study of hyperglycemia.

CP-320626 is a highly efficient human liver glycogen phosphorylase (GP) inhibitor with cholesterol-lowering activity. It inhibits cholesterol biosynthesis by directly inhibiting CYP51 and can be used in type 2 diabetes research.

CP-91149 is a selective glycogen phosphorylase (GP) inhibitor with IC50 of 0.13 μM in the presence of glucose, 5- to 10-fold less potent in the absence of glucose.

AVE 9423 is an allosteric glycogen phosphorylase inhibitor.

1,4-Dideoxy-1,4-imino-D-arabinitol (DAB) functions as an inhibitor of glycogen phosphorylase, a crucial enzyme in glycogenolysis, demonstrating the ability to hinder this process in isolated liver cells (IC50= 1.0 µM) and cerebral cortex and cerebellum homogenates (IC50s = 463 and 383 nM, respectively). Employed extensively in different animal models, DAB inhibits glycogenolysis within the liver and brain.

Ingliforib (CP 368296) is a novel glycogen phosphorylase inhibitor with antihyperglycemic and cardioprotective properties.

Morolic acid and moronic acid have shown sustained antidiabetic and antihyperglycemic action possibly mediated by an insulin sensitization with consequent changes of glucose, cholesterol and triglycerides, in part mediated by inhibition of 11β-HSD 1. Moro